AbbVie is buying an eczema and asthma drug developer for nearly $11 billion
Cris Tolomia
·
2026-06-22
·
via Quartz
The all-cash deal gives AbbVie access to zumilokibart, an experimental drug that could rival Dupixent in trea…
此内容由惯性聚合(RSS阅读器)自动聚合整理,仅供阅读参考。 原文来自 — 版权归原作者所有。